

Danieli Castro O Andrade

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2577146/publications.pdf>

Version: 2024-02-01

60
papers

1,595
citations

393982

19
h-index

329751

37
g-index

67
all docs

67
docs citations

67
times ranked

1729
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Characteristics of Patients With Antiphospholipid Antibody Positivity in the <scp>APS ACTION</scp> International Clinical Database and Repository. Arthritis Care and Research, 2022, 74, 324-335. | 1.5 | 39 |
| 2 | Impact of Distinct Therapies on Antibody Response to <scp>SARSâ€CoV</scp>â€2 Vaccine in Systemic Lupus Erythematosus. Arthritis Care and Research, 2022, 74, 562-571. | 1.5 | 25 |
| 3 | Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients. Journal of Applied Physiology, 2022, 132, 682-688. | 1.2 | 2 |
| 4 | CoaguChekÂ® XS versus standard laboratory prothrombin time for anticoagulant monitoring in patients with antiphospholipid syndrome. Lupus, 2022, 31, 565-574. | 0.8 | 3 |
| 5 | Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 1036-1043. | 0.5 | 30 |
| 6 | Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatric Drugs, 2022, 24, 13-27. | 1.3 | 5 |
| 7 | Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, 2022, 31, 974-984. | 0.8 | 13 |
| 8 | Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (â€Registryâ€™). Lupus Science and Medicine, 2022, 9, e000633. | 1.1 | 9 |
| 9 | Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care and Research, 2021, 73, 1490-1501. | 1.5 | 60 |
| 10 | Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease. Arthritis Care and Research, 2021, 73, 1804-1808. | 1.5 | 7 |
| 11 | Cognitive dysfunction and serum levels of brain-derived neurotrophic factor (BDNF) in primary anti-phospholipid syndrome (PAPS). Rheumatology, 2021, 60, 179-187. | 0.9 | 6 |
| 12 | Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. Journal of Rheumatology, 2021, 48, 541-547. | 1.0 | 19 |
| 13 | Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. Current Rheumatology Reports, 2021, 23, 45. | 2.1 | 9 |
| 14 | Avoiding misclassification of thrombotic primary antiphospholipid syndrome as systemic lupus erythematosus (SLE): What are the best-performing SLE classification criteria?. Lupus, 2021, 30, 1732-1738. | 0.8 | 5 |
| 15 | Distinct features of youth-onset primary antiphospholipid syndrome. Lupus, 2021, 30, 1888-1895. | 0.8 | 0 |
| 16 | Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. Advances in Rheumatology, 2021, 61, 64. | 0.8 | 0 |
| 17 | Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases. PLoS Neglected Tropical Diseases, 2021, 15, e0010002. | 1.3 | 5 |
| 18 | Benefits of Home-Based Exercise Training Following Critical SARS-CoV-2 Infection: A Case Report. Frontiers in Sports and Active Living, 2021, 3, 791703. | 0.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). <i>Lupus</i> , 2021, 30, 2276-2285. | 0.8 | 21 |
| 20 | Diagnosis and Management of Gastric Antral Vascular Ectasia. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 79-81. | 0.5 | 4 |
| 21 | Anorectal diseases in patients with Antiphospholipid syndrome: a cross-sectional study. <i>Advances in Rheumatology</i> , 2020, 60, 51. | 0.8 | 1 |
| 22 | Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363. | 0.8 | 28 |
| 23 | 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593. | 0.8 | 80 |
| 24 | Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). <i>Advances in Rheumatology</i> , 2020, 60, 29. | 0.8 | 4 |
| 25 | A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution. <i>Rheumatology</i> , 2020, 59, 2412-2418. | 0.9 | 19 |
| 26 | Global antiphospholipid syndrome score and anti- β_2 -glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study. <i>Lupus</i> , 2020, 29, 676-685. | 0.8 | 13 |
| 27 | Identification of Autoimmunity to Peptides of Collagen V α_1 Chain as Newly Biomarkers of Early Stage of Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 604602. | 2.2 | 6 |
| 28 | Non-criteria Antiphospholipid Antibodies: a narrative review. <i>Revista Da Associação Médica Brasileira</i> , 2020, 66, 1595-1601. | 0.3 | 4 |
| 29 | Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (<scp>APS</scp>) in the <scp>APS</scp> Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 656-661. | 1.1 | 29 |
| 30 | Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2069-2080. | 1.9 | 9 |
| 31 | The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019, 175, 32-36. | 0.8 | 13 |
| 32 | Clinical and laboratory profile of juvenile-onset systemic sclerosis in a Brazilian cohort. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 43-48. | 1.0 | 2 |
| 33 | Pregnancy outcomes in mixed connective tissue disease: a multicentre study. <i>Rheumatology</i> , 2019, 58, 2000-2008. | 0.9 | 10 |
| 34 | Anti-collagen type v: a marker of early systemic sclerosis?. <i>Advances in Rheumatology</i> , 2019, 59, 19. | 0.8 | 4 |
| 35 | The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468. | 1.6 | 79 |
| 36 | Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia. <i>Autoimmunity Reviews</i> , 2019, 18, 393-398. | 2.5 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Systemic sclerosis induced by the use of cocaine: is there an association?. <i>Rheumatology International</i> , 2019, 39, 387-393. | 1.5 | 12 |
| 38 | The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019, 71, 134-141. | 1.5 | 37 |
| 39 | Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 117-120. | 1.6 | 42 |
| 40 | Eosinophilic fasciitis during pregnancy: case report and review of literature. <i>Rheumatology International</i> , 2018, 38, 525-529. | 1.5 | 1 |
| 41 | Neurologic manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 1404-1414. | 0.8 | 49 |
| 42 | Omega-3 Fatty Acid Supplementation Improves Endothelial Function in Primary Antiphospholipid Syndrome: A Small-Scale Randomized Double-Blind Placebo-Controlled Trial. <i>Frontiers in Immunology</i> , 2018, 9, 336. | 2.2 | 14 |
| 43 | Budd-Chiari syndrome, large regenerative nodules and hepatocellular carcinoma in antiphospholipid syndrome associated with juvenile systemic lupus erythematosus. <i>Modern Rheumatology Case Reports</i> , 2018, 2, 20-24. | 0.3 | 0 |
| 44 | William Habib Chahade 5th October 1941-4th January 2017. <i>Lupus</i> , 2017, 26, 671-671. | 0.8 | 0 |
| 45 | Update on antiphospholipid antibody syndrome. <i>Revista Da Associação Médica Brasileira</i> , 2017, 63, 994-999. | 0.3 | 22 |
| 46 | Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome. , 2017, , 247-266. | | 4 |
| 47 | 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338. | | 19 |
| 48 | Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION). , 2017, , 267-276. | | 1 |
| 49 | AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update. <i>Current Rheumatology Reports</i> , 2016, 18, 64. | 2.1 | 12 |
| 50 | Emerging Therapies in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2016, 18, 22. | 2.1 | 37 |
| 51 | Primary antiphospholipid syndrome: absence of premature atherosclerosis in patients without traditional coronary artery disease risk factors. <i>Lupus</i> , 2016, 25, 472-478. | 0.8 | 19 |
| 52 | ABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis?. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 374-378. | 1.0 | 5 |
| 53 | Interferon- α and Angiogenic Dysregulation in Pregnant Lupus Patients Who Develop Preeclampsia. <i>Arthritis and Rheumatology</i> , 2015, 67, 977-987. | 2.9 | 64 |
| 54 | Difficult Clinical Situations in the Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2015, 17, 29. | 2.1 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Autoimmunity Reviews</i> , 2014, 13, 685-696. | 2.5 | 290 |
| 56 | Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. <i>Arthritis and Rheumatism</i> , 2012, 64, 2719-2723. | 6.7 | 176 |
| 57 | High frequency of osteoporosis and fractures in women with dermatomyositis/polymyositis. <i>Rheumatology International</i> , 2012, 32, 1549-1553. | 1.5 | 21 |
| 58 | Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB/c mice: a promising model for studying human disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 2764-2773. | 6.7 | 45 |
| 59 | Quantifying subclinical central nervous lesions in primary antiphospholipid syndrome: The role of magnetization transfer imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 27, 483-488. | 1.9 | 8 |
| 60 | Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 740-746. | 0.5 | 89 |